https://biotechmorning.com/news/fda-new-cancer-boss-ai-staffing-plan Biotech Morning en 2026-09-12T14:15:31.806Z The FDA's New Cancer Boss Has a Plan (and It Involves Robots) https://biotechmorning.com/news/solstice-oncology-225m-bet-cold-tumors Biotech Morning en 2026-09-12T14:14:50.075Z A $225M Bet That Cold Tumors Can Learn to Fight Back https://biotechmorning.com/news/astrazeneca-camizestrant-serena-4-failure Biotech Morning en 2026-09-12T14:14:05.500Z AstraZeneca's Cancer Pill Got Approved. Eight Days Later, It Flopped. https://biotechmorning.com/news/sma-muscle-targeted-therapy-apitegromab-approval Biotech Morning en 2026-09-12T14:13:23.074Z The Drug That Treats SMA by Ignoring the Root Cause https://biotechmorning.com/news/exelixis-fda-delay-colorectal-cancer Biotech Morning en 2026-09-12T14:12:35.657Z Exelixis Was Three Months From an Answer. Then the FDA Hit Pause. https://biotechmorning.com/news/fda-commissioner-tried-to-kill-kalvista-drug-approval Biotech Morning en 2026-09-12T14:11:54.689Z The FDA Commissioner Who Tried to Kill a Drug Approval https://biotechmorning.com/news/jj-spravato-patent-victory-2035 Biotech Morning en 2026-09-12T14:11:05.463Z J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It. https://biotechmorning.com/news/personalized-mrna-cancer-vaccine-phase-3-win Biotech Morning en 2026-09-12T14:10:23.900Z The Cancer Vaccine That Just Changed Everything https://biotechmorning.com/news/gene-therapy-worst-week-sarepta-crisis Biotech Morning en 2026-09-12T14:09:36.240Z Gene Therapy's Worst Week Just Got Worse https://biotechmorning.com/news/biotech-reverse-mergers-shell-company-shortage Biotech Morning en 2026-09-11T14:19:24.075Z Biotech's Hottest Backdoor Into Wall Street Is Running Out of Keys https://biotechmorning.com/news/kailera-obesity-pill-side-effects Biotech Morning en 2026-09-11T14:18:38.657Z Kailera's Obesity Pill Works. The Side Effects? Yikes. https://biotechmorning.com/news/car-t-prevention-multiple-myeloma Biotech Morning en 2026-09-11T14:17:56.491Z What If You Could Kill Cancer Before It Even Starts? https://biotechmorning.com/news/biohaven-fda-hold-after-350m-deal Biotech Morning en 2026-09-11T14:17:07.572Z Biohaven Signed a $350M Deal. Nine Days Later, the FDA Called. https://biotechmorning.com/news/kura-oncology-diabetes-spinout-caspian-therapeutics Biotech Morning en 2026-09-11T14:16:21.503Z An Oncology Company Just Launched a Diabetes Startup. Wait, What? https://biotechmorning.com/news/abbvie-menstrual-migraine-atogepant-phase-3 Biotech Morning en 2026-09-11T14:15:32.787Z AbbVie Just Found a $6 Billion Problem Nobody Was Solving https://biotechmorning.com/news/andy-plump-takeda-rd-retirement Biotech Morning en 2026-09-11T14:14:46.530Z The Man Who Taught Big Pharma to Date Startups Is Leaving https://biotechmorning.com/news/frazier-life-sciences-1-1-billion-fund-close Biotech Morning en 2026-09-11T14:14:03.723Z Biotech's Funding Winter Has a $1.1 Billion Exception https://biotechmorning.com/news/novartis-shareholder-activist-board-overhaul Biotech Morning en 2026-09-11T14:13:22.790Z Novartis Just Had Its Worst Month in Years. Now Shareholders Want Heads to Roll. https://biotechmorning.com/news/bridgebio-abandons-first-line-kras-lung-cancer Biotech Morning en 2026-09-11T14:12:39.015Z BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer https://biotechmorning.com/news/bms-arlo-cel-car-t-withheld-data Biotech Morning en 2026-09-11T14:11:50.793Z BMS Says Its New CAR-T Worked. It Just Won't Say How Well.